



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lester F. Lau
App. No.: 10/774,706
Conf. No.: 2022
Filing Date: February 9, 2004
Title: CCN1 TRANSGENIC ANIMALS
Art Unit: 1638
Examiner: Not yet assigned

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date:

10/14/2004

Date

Kate Berezutskaya

Kate G. Berezutskaya, Ph.D.

Registration No. 53,984**INFORMATION DISCLOSURE STATEMENT****PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicant calls to the attention of the Examiner references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. Applicant also submits herewith copies for the listed references.

This Information Disclosure Statement is not intended to be an admission that a search has been made, that other relevant art does not exist, or that any of the information disclosed herein constitutes art under 35 U.S.C. §102 or §103.


The Information Disclosure Statement is submitted pursuant to 37 C.F.R. § 1.97 (b) (3) before the mailing of a first Office action on the merits for the above-specified patent application. Therefore, we believe no fee is due with the submission of this Information Disclosure Statement. However,

should any fees be deemed necessary in connection with the filing of this document, the Commissioner is hereby authorized to deduct any such fees from our Deposit Account No. 08-3038.

Respectfully submitted,

HOWREY SIMON ARNOLD & WHITE, LLP

By:



Kate G. Berezutskaya, Ph.D.

Registration No.: 53,984

Customer No.: 22930

Dated: October 14, 2004

HOWREY SIMON ARNOLD & WHITE, LLP

321 N. Clark Street, Suite 3400

Chicago, IL 60661

(312) 595-1239 (main)

(312) 846-5622 (direct)

(312) 264 0364 (fax)



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/774,706
				Filing Date	February 9, 2004
				First Named Inventor	Lester F. Lau
				Group Art Unit	1638
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	05031.0008.NPUS01

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
	A1	6,632,979	10-14-2003	Erickson et al.	
	A2	6,413,735	07-02-2002	Lau	
	A3	6,632,978 B1	10-14-2003	Kaslin et al.	
	A4	6,630,613	10-07-2003	Xu et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)				
	B1	WO 01/55210	08-02-2001	Lau		

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds codes of USPTO Patent Documents as www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/774,706
				Filing Date	February 9, 2004
				First Named Inventor	Lester F. Lau
				Group Art Unit	1638
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	05031.0008.NPUS01

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	C1	Meisner et al (1998). Atrioventricular septal defect. Pediatr Cardiol. 19(4):276-81.	
	C2	Gelb et al. (1997). Molecular genetics of congenital heart disease. Curr Opin Cardiol. 12(3):321-8.	
	C3	Cousineau et al. (1994). Linkage analysis of autosomal dominant atrioventricular canal defects: exclusion of chromosome 21. Hum Genet. 93(2):103-8.	
	C4	Markwald et al. (2000). Conotruncal anomalies in the trisomy 16 mouse: an immunohistochemical analysis with emphasis on the involvement of the neural crest. Anat Rec. 260(3):279-93.	
	C5	Disegni et al. (1985). Two-dimensional echocardiography in detection of endocardial cushion defect in families. Am J Cardiol. 1(55):1649-52.	
	C6	Kumar et al. (1994). Confirmation of linkage of supra-valvular aortic stenosis to the elastin gene on chromosome 7q. Am J Cardiol. 74(12):1281-3.	
	C7	Sheffield et al. (1997). Identification of a complex congenital heart defect susceptibility locus by using DNA pooling and shared segment analysis. Hum Mol Genet. 6(1):117-21.	
	C8	Jay et al. (1997). The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p. Oncogene. 14(14):1753-7.	
	C9	Lau & Lam (1999). The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res. 248(1):44-57.	
	C10	Lau & Nathans (1985). Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J. 4(12):3145-51.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DM_US8056889.v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/774,706
				Filing Date	February 9, 2004
				First Named Inventor	Lester F. Lau
				Group Art Unit	1638
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	05031.0008.NPUS01

C11	Kireeva et al. (1996). Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol. 16(4):1326-34.	
C12	Babic et al. (1998). CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 95(11):6355-60.	
C13	Chen et al. (2001). Heart disease, family history and physical activity. Health Rep. 12(4):23-32.	
C14	Tam (1998). Postimplantation mouse development: whole embryo culture and micro-manipulation. Int J Dev Biol 42:895-902	
C15	Beckman (1997). Mechanisms of amino acid supply to the rat conceptus in normal and abnormal development. Reproductive Toxicology, 11. No. 4: 595-599.	
C16	Kane (2003). A review of in vitro gamete maturation and embryo culture and potential impact on future animal biotechnology. Anim Reprod Sci. 79:171-90.	
C17	Friedrich et al. (1991). Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. Genes Dev. 5:1513-1523	
C18	Mansour et al. (1988). Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 336:348-352	
C19	Li et al. (1992). Targeted Mutation of the DNA Methyltransferase Gene Results in Embryonic Lethality. Cell 69:915-926	
C20	Suri et al. (1998). Increased vascularization in mice overexpressing angiopoietin-1. Science 282:468-471	
C21	Asahara et al. (1998). Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res. 83:233-240	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DM_US\8056889.v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/774,706
				Filing Date	February 9, 2004
				First Named Inventor	Lester F. Lau
				Group Art Unit	1638
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	05031.0008.NPUS01

C22	Eisenberg & Markwardt. (1995). Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res. 77(1):1-6.	
C23	Chen, Mo et al. (2001). The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts. J Biol Chem. 276(50):47329-37.	
C24	Kireeva, Mo et al. (1996). Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol. 16(4):1326-34.	
C25	Cook (2001). The spectrum of fetal cardiac malformations. Cardiol Young 11:97-110	
C26	De la Cruz et al. (2001). Living morphogenesis of the ventricles and congenital pathology of their component parts. Cardiol Young 11:588-600	
C27	Smallhorn (2001). Cross-Sectional Echocardiographic Assessment of Atrioventricular Septal Defect: basic morphology and preoperative risk factors. Echocardiography: a Jnl. Of CV Ultrasound & Allied Tech. 18:415-432.	
C28	Vaughan & Basson (2001). Molecular Determinants of Atrial and Ventricular Septal Defects and Patent Ductus Arteriosus. American J of Medical Genetics 97:304-309.	
C29	Koblizek et al. (1998). Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol. 8(9):529-32.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DM_US\8056889.v1